**STYRELSENS REDOGÖRELSE ENLIGT 13 KAP. 6 § AKTIEBOLAGSLAGEN / *THE BOARD OF DIRECTORS' REPORT IN ACCORDANCE WITH CHAPTER 13, SECTION 6 OF THE SWEDISH COMPANIES ACT***

Som redogörelse enligt 13 kap. 6 § aktiebolagslagen får styrelsen i Magle Chemoswed Holding AB, org.nr 556913-4710, anföra följande.

*The board of directors of Magle Chemoswed Holding AB, reg. no. 556913-4710, submits the following report in accordance with Chapter 13, Section 6 of the Swedish Companies Act.*

Efter avlämnandet av årsredovisningen för räkenskapsåret 2025 har inga händelser av väsentlig betydelse för bolagets ställning inträffat utöver vad som framgår av regulatoriska pressmeddelanden och kvartalsrapporter som offentliggjorts på bolagets webbplats, https://maglegroup.com/, även bilagda denna redogörelse.

*After the submission of the annual report for the financial year 2025, no events of material importance to the company's financial position have occurred other than what is presented in the regulatory press releases and quarterly reports which have been published on the Company's website, https://maglegroup.com/, also attached to this statement.*

_____

Malmö den 10 juli 2026 / *Malmö on 10 July 2026*

**Magle Chemoswed Holding AB**

*Styrelsen / The board of directors*

*Stig Løkke Pedersen*

_____

Stig Løkke Pedersen (ordförande / *chairman*)

*Tom Rönnlund*

_____

Tom Rönnlund

*Søren Skjold Mogensen*

_____

Søren Skjold Mogensen

Press Release
June 30, 2026

# Magle Group enters into agreement with Danske Bank regarding repayment schedule and agreement with the bondholders committee regarding the requirement for additional capital

**Magle Chemoswed Holding AB (publ) ("Magle" or the "Company") has today, on 30 June 2026, entered into (i) an agreement with Danske Bank A/S regarding repayment schedule and (ii) an agreement with the bondholders' committee regarding the requirement for additional capital.**

## Agreed repayment schedule

As previously disclosed on 7 June 2026, the Company has a SEK 32.5 million credit facility with Danske Bank A/S (the "**Danske Bank Facility**") which was scheduled to mature on 30 June 2026. The Company today, on 30 June 2026, announces that it has reached an agreement with Danske Bank A /S regarding a structured repayment schedule for the outstanding amount under the Danske Bank Facility. The key terms of the agreed repayment schedule are as follows:

- a repayment of SEK 15 million to be made by 31 August 2026;
- the remaining outstanding amount to be repaid by 30 October 2026; and
- interest for the extended period to accrue at the ordinary rate of STIBOR 90 +1.75% applicable under the Danske Bank Facility (i.e., not at any default rate).

The agreed repayment schedule provides the Company with additional time to manage its liquidity position and supports the Company's continued operations and long-term development.

## Agreement with the bondholders' committee regarding the requirement for additional capital

Pursuant to the written procedure in respect of its senior secured floating rate bonds with ISIN SE0025197403 submitted by the Company on 26 March 2026, and accepted by the bondholders on 23 April 2026, the bondholders agreed that the maintenance test contained in the terms and conditions for the bonds should not be tested on the reference dates falling 31 December 2025 until (and including) 31 December 2026, provided that, if the Issuer fails to raise no less than SEK 100 million, or such lower amount as agreed between the Company and the bondholders' committee, by 30 June 2026, the maintenance test shall be reinstated.

As part of the ongoing discussions between the Company and the bondholders' committee regarding a restructuring of the Company's outstanding financing, the bondholders' committee has today, on 30 June 2026, agreed that the amount required to be raised by the Company for the maintenance test to not be reinstated shall be equal to zero.

## Contacts

Aaron Wong, Interim CEO, CFO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com

## About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. Today, the Group includes two operational areas. Magle Chemoswed – a contract manufacturing organization (CMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle Biopolymers A/S - a specialized manufacturing organization of Dextran technology. Learn more on **www.maglechemoswed.com** and **www.maglegroup.com** and **www.maglebiopolymers.com**

Redeye Nordic Growth AB is the company's Certified Adviser.

*This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-06-30 21:53 CEST.*

## Attachments

Magle Group enters into agreement with Danske Bank regarding repayment schedule and agreement with the bondholders committee regarding the requirement for additional capital